Financial Summary for the Second Quarter of the Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)

Overview of Results

For the interim period, net sales amounted to 808,544 million yen, a 5.3% increase from the same period of the previous fiscal year, while operating income decreased significantly to 4,748 million yen (down 34.6%). Pharmaceutical wholesale remained steady, but higher raw material costs and increased expenses weighed on profits. By segment, pharmaceutical wholesale accounted for the largest share of sales, with dispensing pharmacies, pharmaceutical manufacturing and sales, and other peripheral businesses also contributing. Interim net income was 4,177 million yen, down 33.1% year-over-year. The full-year forecast remains unchanged. The company will continue to promote new alliances and strengthen its management foundation through DX and other initiatives.

Strategy and Future Outlook

As part of the mid-term management plan "Soaring into the Next Era," the company is promoting growth strategies, efficiency improvements, and reinforcement of the management foundation. The company is expanding alliances and new business creation (including Allostem Sheet, Stemchymal, AdipoSeeds, etc.). It will pursue logistics and delivery efficiency, reduce indirect material costs, and streamline operations through DX, aiming to transform into a healthcare total solution provider. Measures to respond to external environmental changes such as drug price revisions will continue.